Valve function during graft rejection and before graft failure in pediatric heart transplant recipients

<h2>Abstract</h2><h3>Objective</h3> Management of immunosuppression after human valve transplant remains unclear and may be aided by understanding valve function during rejection and with chronic graft failure after heart transplant. We assessed valve function during biopsy-diagnosed rejection and before death/retransplantation in pediatric heart transplant recipients. <h3>Methods</h3> This was a single-center, retrospective study. Patients in cohort 1 had 2 serial biopsies showing nonrejection followed by rejection and concurrent echocardiograms. Cohort 2 had graft loss (death or retransplant) with a pre-event echocardiogram. <h3>Results</h3> In cohort 1 (n = 86), the median age at heart transplant was 12.0 years, and the median time between heart transplant and rejection was 2.6 years. No patient had more than trivial aortic regurgitation at baseline or during rejection. Mild pulmonary regurgitation was present in 2 patients (2.3%) at baseline and 4 patients (4.8%) during rejection (<i>P =</i> .10). Patients with mild or greater mitral regurgitation increased from 13 patients (15.1%) at baseline to 29 patients (33.7%) during rejection (<i>P <</i> .001). Worse mitral regurgitation during rejection was more likely in conjunction with moderate or greater left ventricular dysfunction (64.8% vs 8.7%, <i>P <</i> .001). In cohort 2 (n = 51), the median duration between heart transplant and graft loss was 8.4 years. Mild or greater aortic regurgitation was present in 1 patient (2.0%), pulmonary regurgitation mild or greater was present in 4 patients (7.8%), and mitral regurgitation mild or greater was present in 20 patients (39.2%). No patient developed valve stenosis. <h3>Conclusions</h3> In a series of more than 100 pediatric heart transplant recipients, semilunar valve dysfunction was rare, suggesting that contemporary immunosuppression is sufficient to preserve the longevity of semilunar valve transplants. Mitral valve dysfunction was more common, often associated with left ventricular dysfunction, and warrants further study.

Authors

Institutions

Publication Details

Journal
JTCVS Open
Published
2025-11-24
DOI
https://doi.org/10.1016/j.xjon.2025.11.018
Primary Topic
Transplantation: Methods and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Valve function during graft rejection and before graft failure in pediatric heart transplant recipients

Addison Gearhart, Tajinder P. Singh, Sitaram M. Emani, Stuart R. Lipsitz et al.
JTCVS Open
Transplantation: Methods and Outcomes
article

Valve function during graft rejection and before graft failure in pediatric heart transplant recipients

Addison Gearhart, Tajinder P. Singh, Sitaram M. Emani, Stuart R. Lipsitz, Yuanyuan Fu, Gianna Dafflisio
article en

Abstract

<h2>Abstract</h2><h3>Objective</h3> Management of immunosuppression after human valve transplant remains unclear and may be aided by understanding valve function during rejection and with chronic graft failure after heart transplant. We assessed valve function during biopsy-diagnosed rejection and before death/retransplantation in pediatric heart transplant recipients. <h3>Methods</h3> This was a single-center, retrospective study. Patients in cohort 1 had 2 serial biopsies showing nonrejection followed by rejection and concurrent echocardiograms. Cohort 2 had graft loss (death or retransplant) with a pre-event echocardiogram. <h3>Results</h3> In cohort 1 (n = 86), the median age at heart transplant was 12.0 years, and the median time between heart transplant and rejection was 2.6 years. No patient had more than trivial aortic regurgitation at baseline or during rejection. Mild pulmonary regurgitation was present in 2 patients (2.3%) at baseline and 4 patients (4.8%) during rejection (<i>P =</i> .10). Patients with mild or greater mitral regurgitation increased from 13 patients (15.1%) at baseline to 29 patients (33.7%) during rejection (<i>P <</i> .001). Worse mitral regurgitation during rejection was more likely in conjunction with moderate or greater left ventricular dysfunction (64.8% vs 8.7%, <i>P <</i> .001). In cohort 2 (n = 51), the median duration between heart transplant and graft loss was 8.4 years. Mild or greater aortic regurgitation was present in 1 patient (2.0%), pulmonary regurgitation mild or greater was present in 4 patients (7.8%), and mitral regurgitation mild or greater was present in 20 patients (39.2%). No patient developed valve stenosis. <h3>Conclusions</h3> In a series of more than 100 pediatric heart transplant recipients, semilunar valve dysfunction was rare, suggesting that contemporary immunosuppression is sufficient to preserve the longevity of semilunar valve transplants. Mitral valve dysfunction was more common, often associated with left ventricular dysfunction, and warrants further study.

JTCVS OpenVol. 29
Boston Children's Hospital (US), Harvard University (US)
American Heart Association
Openalex Percentile: Top 45%
Transplantation: Methods and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.